Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

“I saw in Louisiana a live-oak growing / All alone stood it, and the moss hung down from the branches.” —Walt Whitman, Leaves of Grass, 1860-61 More than 150 years after Whitman wrote those lines, the ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

From Estonia to Antarctica, this once-pagan symbol has taken on many strange forms. In December 1848, an illustration showed Queen Victoria, Prince Albert, and their children admiring a Christmas tree ...

Steve Nix is a member of the Society of American Foresters and a former forest resources analyst for the state of Alabama. According to National Wildlife Federation, there are two varieties of Douglas ...

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...